Mounjaro and Cannabis: Separating Fact from Assumption

The biggest myth: 'cannabis is natural, so it can't interfere'

It's a common assumption, and an understandable one. Cannabis is plant-derived, widely used, and many people have taken it alongside prescription medicines without obvious problems. The issue is that 'natural' says nothing about pharmacological effect. Cannabis contains dozens of active compounds, most notably THC and CBD, both of which interact with the body's endocannabinoid system and affect appetite, nausea, gut motility, liver enzymes and the metabolism of other substances.

THC is a well-established appetite stimulant. Tirzepatide works, in part, by suppressing appetite through dual GIP and GLP-1 receptor activation, the only licensed medicine in the UK to target both pathways simultaneously, as described in the NHS tirzepatide medicines guide. Combining a drug that reliably increases appetite with one designed to reduce it creates an obvious tension. Whether that tension significantly blunts weight-loss outcomes in practice is not yet quantified, but it is a reasonable clinical concern.

CBD is metabolised through the CYP450 enzyme system, specifically CYP3A4 and CYP2C9. Tirzepatide does not appear to be a major CYP3A4 substrate, but gut motility changes caused by tirzepatide may alter the absorption rate of other substances taken orally, including CBD products. This is worth flagging to your prescriber, especially if you use high-dose oral CBD.

Nausea, appetite and the adjustment period, where overlap matters most

The first few weeks of Mounjaro are when most people experience the strongest gastrointestinal side effects: nausea, changes in bowel habit, and reduced appetite that can feel sudden. These usually ease as the body adjusts. Cannabis (particularly strains high in CBD) is sometimes used to manage nausea. Some users find this helpful. Others find that THC-driven appetite stimulation during the adjustment phase undermines the appetite-reduction they were hoping for from tirzepatide.

There is also the question of caloric intake. If cannabis causes strong munchies, and you act on them, the calorie deficit that tirzepatide helps create narrows. Over months, that can meaningfully affect your results. This isn't a moral judgement about cannabis use; it's a straightforward physiological point. Our prescribers see a wide range of patient situations, if you're curious how this might apply to your own circumstances, the Mounjaro FAQ page covers many of the most common questions about what affects treatment outcomes.

For people who use cannabis primarily for conditions such as chronic pain, anxiety, or poor sleep, there may be additional complexity around why those conditions themselves are being treated and whether they overlap with the health picture Mounjaro is being considered for. Mounjaro and MS and Mounjaro and IBS are separate topics we've covered, both of which touch on how underlying conditions factor into the prescribing decision.

What your prescriber needs to know, and why honesty matters here

There is no requirement under UK law for a prescriber to refuse treatment solely because a patient uses cannabis. What there is, under good clinical practice, is an obligation to make a fully informed prescribing decision. That means knowing what you take. Cannabis is not currently a contraindication listed in the Mounjaro SmPC, but it can affect the clinical picture in ways that matter: appetite, weight-loss trajectory, gut symptoms, and (if you smoke it) cardiovascular and respiratory factors that interact with the broader reasons weight management has been recommended.

Withholding this information from a prescriber doesn't protect you; it removes a layer of clinical judgement that exists for your benefit. At nume, every consultation is read by a GPhC-registered Independent Prescriber, not processed by an algorithm. A real clinician reads your answers and makes an individual assessment. If you use cannabis and have questions about HRT interactions as well, tirzepatide and HRT is worth reading alongside this page, the underlying question of 'what else am I taking' is the same.

The MHRA's public guidance on GLP-1 medicines for weight loss makes clear these treatments are for use within a clinically supervised framework, not as a standalone intervention. Mounjaro is a tirzepatide-based treatment authorised for weight management alongside diet and activity changes, and that clinical framework is where questions like this one get properly answered. You can explore what else affects Mounjaro prescribing decisions, including less-discussed interactions, on our Mounjaro overview page.

When to get medical help during treatment

If you are using cannabis and taking tirzepatide, pay attention to any overlap in symptoms. Both substances can cause dizziness and changes in heart rate; both affect the gut. If you experience severe, persistent abdominal pain that radiates to the back, seek urgent medical attention, this can be a sign of pancreatitis, which the MHRA flagged as a known, if infrequent, side effect of GLP-1 medicines in a January 2026 Drug Safety Update. That warning applies regardless of what else you take alongside. You can report any suspected side effects via the MHRA Yellow Card scheme.

If you notice that nausea is particularly severe, or that your appetite suppression feels absent rather than reduced, mention it to your prescriber at your next review. These are the kinds of signals that, in context, matter.

If you'd like a prescriber to look at your full situation, start a free consultation with our team.